NIH

Vanderbilt investigators have discovered a novel non-genetic cause of resistance to the targeted anti-cancer therapy cetuximab. Their findings, reported this week in Nature Medicine, suggest a strategy for overcoming this resistance.

Vanderbilt investigators have developed a new mouse model of kidney fibrosis, which provides a platform for identifying new targets and treatment strategies.

Vanderbilt investigators have discovered a class of compounds that inhibit a mediator of inflammation and autoimmune disorders, and that could pave the way for development of future therapies.

A compound identified at Vanderbilt represents a new lead for treating rare, aggressive childhood cancers called Ewing sarcomas.

Vanderbilt scientists have taken an important step toward understanding the way in which injured cells trigger wound healing, an insight essential for improving treatments of all types of wounds.

With other risk factors held equal, children who received a benzodiazepine sedative drug were nearly three times more likely to experience delirium – confused thought – the following day.

New mechanistic details about the DNA-unwinding activity of antibacterial protein targets could lead to the design of better antibiotic medicines.